<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="ribavirin, remdesivir and galidesivir act as RDRP inhibitors while lopinavir," exact="ritonavir" post="[5,6] and danoprevir are viral protease inhibitors. In addition,"/>
 <result pre="of the viral particles have been proposed, such as chloroquine," exact="hydroxychloroquine" post="[7] and APN01 [8]. Lopinavir and ritonavir designed and"/>
 <result pre="such as chloroquine, hydroxychloroquine [7] and APN01 [8]. Lopinavir and" exact="ritonavir" post="designed and approved for the treatment of AIDS were"/>
 <result pre="and dolutegravir [13] and the HIV-1 protease inhibitors, darunavir and" exact="saquinavir" post="[14]. According to a more recent in silico research,"/>
 <result pre="silico research, published on April 15th, the HCV protease inhibitors," exact="simeprevir" post="and faldaprevir as well as the HIV-1 protease inhibitors"/>
 <result pre="faldaprevir as well as the HIV-1 protease inhibitors indinavir and" exact="tipranavir" post="along with saquinavir were predicted to act as better"/>
 <result pre="as the HIV-1 protease inhibitors indinavir and tipranavir along with" exact="saquinavir" post="were predicted to act as better Mpro inhibitors compared"/>
 <result pre="predicted to act as better Mpro inhibitors compared to the" exact="lopinavir" post="and ritonavir used in clinical practice [15]. Danoprevir was"/>
 <result pre="act as better Mpro inhibitors compared to the lopinavir and" exact="ritonavir" post="used in clinical practice [15]. Danoprevir was the first"/>
 <result pre="the random selection was made for the HIV-1 inhibitors where" exact="lopinavir" post="and ritonavir were selected because they have already been"/>
 <result pre="selection was made for the HIV-1 inhibitors where lopinavir and" exact="ritonavir" post="were selected because they have already been proposed for"/>
 <result pre="of the drugs that were selected are the anti-HCV drugs" exact="telaprevir" post="and boceprevir, the DPP-4 inhibitor sitagliptin, the renin inhibitor"/>
 <result pre="inhibitor alisliren, the ACE inhibitor captopril, the thrombin direct inhibitors" exact="argatroban" post="and dabigatran and the coagulation Factor Xa inhibitor rivaroxaban."/>
 <result pre="compounds, with the exception of the ACE and renin inhibitors," exact="captopril" post="and aliskiren, for which the calculated free binding energy"/>
 <result pre="The best results were obtained for the HCV protease inhibitors" exact="telaprevir" post="and boceprevir, with free binding energies of âˆ’10.05 and"/>
 <result pre="âˆ’9.03 and âˆ’8.80 kcal molâˆ’1, respectively. The HIV-1 protease inhibitors" exact="ritonavir" post="and lopinavir showed a little lower predicted activity, with"/>
 <result pre="âˆ’8.80 kcal molâˆ’1, respectively. The HIV-1 protease inhibitors ritonavir and" exact="lopinavir" post="showed a little lower predicted activity, with free binding"/>
 <result pre="active site is the second preferred binding site of lopinavir," exact="ritonavir" post="and boceprevir. According to this observation, the expected inhibitory"/>
 <result pre="the DPP-4 inhibitors. In the group of anti-coagulants, inogartan and" exact="argatroban" post="of the first randomly selected compounds were the most"/>
 <result pre="at the S1 subsite such as the 7-methoxy-8-methyl-quinoline moiety of" exact="simeprevir" post="[15] or the oxadiazole group of raltegravir, which adopts"/>
 <result pre="role in complex stabilization of many compounds including raltegravir and" exact="ribavirin" post="[12]. Most inhibitors used in this study do not"/>
 <result pre="protease inhibitors, teneligliptin and gemigliptin but also trelagliptin, evogliptin and" exact="gosogliptin" post="among the DPP-4 inhibitors, inogatran and melagatran of Î±-thrombin"/>
 <result pre="approved drugs characterized as well tolerated in subjects. Compared to" exact="lopinavir" post="and ritonavir, most of the evaluated compounds showed better"/>
 <result pre="TechniquesMath. Oper. Res.19816193010.1287/moor.6.1.19 41.A Phase 3 Study in Combination with" exact="BMS-790052" post="and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsAvailable"/>
 <result pre="coagulation Factor Xa heavy chain (B). Figure 3 Docking of" exact="linagliptin" post="(A,C) and gemigliptin (B,D) at the SARS-CoV-2 structure 6M2N."/>
 <result pre="indinavir, lasinavir, lopinavir, mozenavir, nelfinavir, palinavir, ritonavir, saquinavir, telinavir, and" exact="tipranavir" post="HCV Protease asunaprevir, boceprevir, ciluprevir, danoprevir, faldaprevir, narlaprevir, neceprevir,"/>
 <result pre="gemigliptin, gosogliptin, linagliptin, melogliptin, omarigliptin, saxagliptin, sitagliptin, teneligliptin, trelagliptin, and" exact="vildagliptin" post="Renin aliskiren, ciprokiren, ditekiren, enalkiren, remikiren, terlakiren, and zankiren"/>
 <result pre="pivopril, quinapril, ramipril, rentiapril, spirapril, temocapril, trandolapril, utibapril, zabicipril, and" exact="zofenopril" post="Thrombin direct inhibitors: argatroban, inogatran, melagatran and its pro-drug"/>
 <result pre="Active Site (kcal molâˆ’1) HIV-1 protease inhibitors Lopinavir âˆ’8.65 (2nd)" exact="Ritonavir" post="âˆ’8.96 (2nd) HCV protease inhibitors Telaprevir âˆ’9.23 Boceprevir âˆ’9.16"/>
 <result pre="inhibitors Lopinavir âˆ’8.65 (2nd) Ritonavir âˆ’8.96 (2nd) HCV protease inhibitors" exact="Telaprevir" post="âˆ’9.23 Boceprevir âˆ’9.16 (2nd) DPP-4 inhibitor Sitagliptin âˆ’8.80 Thrombin"/>
 <result pre="HCV protease inhibitors Telaprevir âˆ’9.23 Boceprevir âˆ’9.16 (2nd) DPP-4 inhibitor" exact="Sitagliptin" post="âˆ’8.80 Thrombin inhibitors Argatroban âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa"/>
 <result pre="âˆ’8.80 Thrombin inhibitors Argatroban âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa inhibitor" exact="Rivaroxaban" post="âˆ’7.97 ACE inhibitor Captopril âˆ’5.17 Renin inhibitor Aliskiren âˆ’4.66"/>
 <result pre="âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa inhibitor Rivaroxaban âˆ’7.97 ACE inhibitor" exact="Captopril" post="âˆ’5.17 Renin inhibitor Aliskiren âˆ’4.66 molecules-25-02529-t003_Table 3Table 3 Estimated"/>
 <result pre="âˆ’6.02 Evogliptin âˆ’8.38 âˆ’8.74 âˆ’9.84 Narlaprevir âˆ’5.70 âˆ’6.11 âˆ’12.38 âˆ’6.90" exact="Gosogliptin" post="âˆ’8.30 âˆ’8.75 âˆ’9.18 Sovaprevir âˆ’8.17 âˆ’8.53 âˆ’10.45 âˆ’4.80 Gemigliptin"/>
 <result pre="Teneligliptin âˆ’9.58 âˆ’9.16âˆ’9.52 * âˆ’9.87 âˆ’6.55 Trelagliptin âˆ’8.92 âˆ’8.41 âˆ’9.30" exact="Vildagliptin" post="âˆ’8.55 âˆ’8.21 âˆ’8.67 4FFW initial ligand (sitagliptin) âˆ’10.78 Î±-Thrombin"/>
 <result pre="6M2N 1DWE 6LU7 6M2N 4BTI Inogatran âˆ’10.30 (3rd) âˆ’8.32 âˆ’10.39" exact="Apixaban" post="âˆ’7.53 âˆ’7.11 Melagatran âˆ’8.64 âˆ’8.70 âˆ’10.35 Betrixaban âˆ’9.25 âˆ’8.44"/>
 <result pre="Fast Track status from FDA in 2012 Achillion Pharmaceuticals -" exact="Telaprevir" post="ChEMBL231813 Approved 2011 Vertex Pharmaceuticals and Johnson &amp;amp; Johnson"/>
 <result pre="Gemigliptin - Approved 2011 LG Life Sciences Generally well tolerated" exact="Gosogliptin" post="- Approved in Russia 2016 Pfizer Hypoglycemia [48] Linagliptin"/>
 <result pre="AstraZeneca Upper respiratory tract infection, may cause joint pain [49,50]" exact="Sitagliptin" post="ChEMBL1422 Approved 2006 Merck &amp;amp; Co. Headache, swelling of"/>
 <result pre="Trelagliptin - Approved in Japan 2015 Takeda Generally well tolerated" exact="Vildagliptin" post="ChEMBL142703 Approved 2007 Novartis Nausea, hypoglycemia, headache, dizziness [52]"/>
 <result pre="tolerated Melagatran AstraZeneca Dabigatran ChEMBL539697 Approved 2010 Boehringer-Ingelheim Gastrointestinal [54]" exact="Apixaban" post="ChEMBL231779 Approved 2014 Bristol-Myers Squibb and Pfizer Bleeding, bausea"/>
</results>
